Clinical Research Directory

Inclusion Criteria: * Signed informed consent form prior to any study-specific procedures. * Male or female ≥40 to ≤80 years of age at Screening Visit. * Physician diagnosis of COPD for at least 2 years prior to the Screening Visit in accordance with the definition by the American Thoracic Society/European Respiratory Society * Current or former smokers with a cigarette smoking history of ≥10 pack years at the Screening Visit calculated as (number of pack years = \[number of cigarettes per day/20\] multiplied by number of years smoked). Former smokers are defined as those who meet the pack-year history but have stopped smoking for at least 6 months prior to the Screening Visit. * Spirometry: post-BD FEV1/FVC \<0.70 and post-BD FEV1 \>20% and ≤60% of predicted normal values at the Screening Visit. * Documented history of exacerbation risk defined as exacerbation history of ≥1 moderate\* or ≥1 severe\*\* within 2 years prior to the Screening Visit. * Background ICS-based therapy (ICS+ long-acting β2 agonist \[LABA\], or ICS + long-acting muscarinic antagonist \[LAMA\], or ICS + LAMA + LABA) for ≥12 weeks prior to enrollment with a stable dose of medication for ≥4 weeks prior to the Screening Visit. * Evidence of an eosinophilic phenotype: Participants with blood eosinophils ≥0.30x109/L at the Screening Visit. * Negative urine pregnancy test for women of childbearing potential (WOCBP) at the Screening and Baseline Visits. * WOCBP (after menarche) must use e methods of birth control from the Screening Visit through the End of Study Visit.. Exclusion Criteria: * A current diagnosis of asthma or any history of asthma diagnosis when ≥40 years of age. * Significant pulmonary disease other than COPD (eg, α-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, lung cancer, clinically significant bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated eosinophil counts. * Pneumonia, upper or lower respiratory tract infection or acute exacerbation of COPD within 4 weeks prior to or during the Screening Phase. * Treatment with a biologic investigational drug in the last 5 months prior to the Screening Visit. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to the Screening Visit, whichever is longer. Treatment with GSK3511294 (long-acting anti-interleukin-5) in the past 12 months. * Treatment with any of the following monoclonal antibody therapies within 120 days prior to the Baseline Visit: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. * Treatment with pramipexole (Mirapex®) within 30 days of the Baseline Visit. * Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to the Screening Visit. * Treatment with selected drugs known to have a substantial risk of QT prolongation in the past 30 days prior to the Screening Visit. * Participants who are participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation. * History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 2 years prior to the Baseline Visit. * History of human immunodeficiency virus infection or chronic infection with hepatitis B or C. * Neutrophil count \<2.000x109/L at the Screening Visit. * Renal dysfunction, defined as an estimated glomerular filtration rate \<60 mL/min/1.73m2 at the Screening Visit (using the Chronic Kidney Disease Epidemiology Collaboration) formula. * Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at the Screening Visit confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. * History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%. * Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at the Screening Visit or QTcF ≥480 ms for participants with bundle branch block. * Pregnant women or women breastfeeding. * Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide). * The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.